Valeant Pharmaceuticals, Vuzix, Tiffany News Today

Valeant Pharmaceuticals Intl Inc, Vuzix Corporation, and Tiffany are in the news today

by Karee Venema

Published on Mar 17, 2017 at 9:30 AM
Updated on Mar 17, 2017 at 9:39 AM

Stock futures are trading near fair value ahead of today's G-20 summit, which will include U.S. Treasury Secretary Steven Mnuchin. Among stocks in focus are pharmaceutical firm Valeant Pharmaceuticals Intl Inc (NYSE:VRX), wearable tech name Vuzix Corporation (NASDAQ:VUZI), and luxury retailer Tiffany stock, Here's a quick roundup of the headlines moving shares of VRX, VUZI, and TIF stock.

ValueAct Gives Valeant Pharmaceuticals a Post-Ackman Nod

VRX stock is trading up 4.2% ahead of the bell, after closing last night at $11.20. Boosting the shares is news that ValueAct increased its stake in Valeant Pharmaceuticals Intl Inc to 5.2%, calling the shares "undervalued." This comes just days after Bill Ackman announced he threw in the towel on his losing VRX bet. Valeant shares could definitely use some upside, considering they've shed nearly 23% year-to-date -- and roughly 67% year-over-year. Short sellers have certainly been on the winning side of VRX, too, with more than 11% of the stock's float sold short.

Earnings Have Vuzix Stock at Risk of Erasing 2017 Gains

Shares of VUZI are down 11.9% in electronic trading, after the company's fourth-quarter revenue came up far short of the consensus estimate. Today's projected price move could send the shares back into the red on a year-to-date basis. A continued struggle could prompt a round of bearish brokerage notes from the upbeat analyst bunch. Three analysts currently cover Vuzix Corporation, each of which has issued a "buy" rating toward the stock. Plus, the average 12-month price target of $10.50 stands at a 45.8% premium to last night's close at $7.20 and territory not charted in six years.

TIF Stock Set to Pop After Earnings Win

TIF stock is set to climb 3.7% out of the gate to a fresh annual high, after the retailer turned in better-than-expected earnings and an encouraging forecast. Tiffany shares have already had an impressive run in 2017, up 16.2%, based on last night's settlement at $89.98. TIF options traders have been buying to open calls over puts at a faster-than-usual clip ahead of earnings, too. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), TIF's 10-day call/put volume ratio of 1.20 ranks in the elevated 63rd annual percentile.

Get a jump-start on the day's stock market news with Schaeffer's free Opening View newsletter.

a schaeffer's exclusive


5 tips to leverage profits in this FREE insider report!



NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories

The Trend Minting Millionaires -- But Who Is Really Paying?
Porter Stansberry is making a concerning prediction.
Merck Makes Big Move For Cancer Drug Developer
MRK is fresh off a 19-year high from Friday
ATVI Stock Gets Price-Target Bump as it Rides Chart Support
Short interest on Activision Blizzard is at a 3-year high
The Trend Minting Millionaires -- But Who Is Really Paying?
Porter Stansberry is making a concerning prediction.